BRAF and cancer: This has been demonstrated by loss of heterozygosity analysis at key loci where deletion events associated with late- compared to early-stage BRAF mutant/MSS cancers overall and at loci on 5q, 17p, and 18q, and loss at 18q and 8p correlated with worse survival [10].